Skip to main content

Table 3 Univariate analysis of mutated genetic pathways, DDR genes, and recurrence survival rate

From: Prognostic factors of non-muscle invasive bladder cancer: a study based on next-generation sequencing

Genetic pathway Total patients (n = 58) BCG subgroup (n = 46)
P-value Hazard ratio (95% CI) P-value Hazard ratio (95% CI)
Qualitative
Epigenetic-related genes 0.020 0.278 (0.095–0.814) 0.023 0.198 (0.049–0.797)
TP53/cell cycle pathway 0.668 0.805 (0.299–2.170) 0.725 0.790 (0.212–2.942)
RTK-PI3K pathway 0.830 0.849 (0.192–3.765) 0.351 0.473 (0.098–2.280)
SWI/SNF pathway 0.182 0.424 (0.120–1.497) 0.397 0.507 (0.105–2.439)
DNA damage pathway 0.554 0.710 (0.229–2.204) 0.965 0.969 (0.242–3.878)
Alternative splicing pathway 0.059 0.240 (0.054–1.056) 0.289 0.427 (0.089–2.056)
DDR genes 0.298 2.931 (0.387–22.211) 0.632 1.662 (0.208–13.306)
Quantitative
Epigenetic-related genes 0.960 0.993 (0.756–1.303) 0.877 1.030 (0.710–1.494)
TP53/cell cycle pathway 0.942 1.016 (0.665–1.553) 0.958 0.985 (0.566–1.716)
RTK-PI3K pathway 0.096 0.686 (0.440–1.069) 0.308 0.756 (0.441–1.295)
SWI/SNF pathway 0.170 0.567 (0.252–1.275) 0.379 0.671 (0.276–1.632)
DNA damage pathway 0.319 0.700 (0.348–1.411) 0.582 0.810 (0.382–1.716)
Alternative splicing pathway 0.101 0.400 (0.134–1.195) 0.410 0.629 (0.208–1.897)
DDR genes 0.603 0.951 (0.788–1.148) 0.808 0.974 (0.789–1.203)
  1. DDR: DNA damage response and repair; BCG: Bacillus Calmette–Guérin; CI: confidence interval; RTK: receptor tyrosine kinases; PI3K: phosphatidylinositol 3-kinase; SWI/SNF: Switch/sucrose nonfermentable; n: number